AUS
NZ
UK
CA
USA
IND
Healthcare
Verona Pharma (NASDAQ:VRNA) Reports Q3 2024 Results with Promising Ohtuvayre™ Launch
November 04, 2024 12:07 AM PST| By Team Kalkine MediaHighlights:,Ohtuvayre™ generates $5.6 million in net sales in its first seven weeks, signaling a strong market entry.,October sales outpace Q3 performance with over 5,000 prescriptions filled.,Robust cash position of $336 million to support operation...
QIAGEN (NYSE:QGEN) Receives FDA Clearance for QIAstat-Dx Meningitis/Encephalitis Panel
November 04, 2024 12:05 AM PST| By Team Kalkine MediaHighlights:,QIAGEN secures fourth FDA clearance in 2024, enhancing its diagnostic offerings.,Rapid results in just one hour revolutionize the diagnosis of central nervous system infections.,Advanced technology provides detailed clinical insights with...
Coronation Fund Managers Reduces Stake in Revvity, Inc.
November 03, 2024 10:16 AM PST| By Team Kalkine MediaHeadlines,Coronation Fund Managers decreased its stake in Revvity, Inc. during the third quarter.,Major institutional investors are showing dynamic movements in their Revvity holdings.,Revvity sees significant interest from leading institutional fund...
Elevance Health Attracts Increased Institutional Investment
November 03, 2024 08:43 AM PST| By Team Kalkine MediaHeadlines,Coronation Fund Managers enhances Elevance Health stake,Notable hedge fund activity reflects confidence in Elevance Health,Elevance Health demonstrates strong financial metrics and stability,Coronation Fund Managers Ltd. has recently increa...
What Does the Performance of The Cooper Companies Tell Us?
October 30, 2024 07:06 AM PDT| By Team Kalkine MediaHighlights,The Cooper Companies experiences a significant increase in share price over the last year.,Long-term returns have not met market averages, raising questions about performance.,Revenue growth indicates management's focus may be on expansion...
Edwards Lifesciences (NYSE:EW) benefits from a rating upgrade by Sanford C. Bernstein
October 30, 2024 04:57 AM PDT| By Team Kalkine MediaHighlights,Edwards Lifesciences received an upgrade from "strong sell" to "hold" from Sanford C. Bernstein amid a challenging market environment.,The company reported earnings that met analyst estimates but experienced a decline in revenue compared t...
Eli Lilly's shares face a decline due to unmet quarterly profit estimates
October 30, 2024 04:17 AM PDT| By Team Kalkine MediaHighlights,Eli Lilly reported third-quarter profits that fell short of Wall Street estimates, primarily due to higher manufacturing costs and a substantial acquisition-related charge.,Sales of key products, Mounjaro and Zepbound, were lower than anti...
How Did BrainStorm Cell Therapeutics Regain Nasdaq Compliance?
October 30, 2024 04:07 AM PDT| By Team Kalkine MediaHighlights,BrainStorm Cell Therapeutics announces compliance with Nasdaq's listing requirements.,The company specializes in autologous stem cell therapies for neurodegenerative diseases.,Regaining compliance opens doors for continued market presence...
Vera Therapeutics (NASDAQ:VERA) receives a new price target of $64.00 from Guggenheim
October 30, 2024 03:45 AM PDT| By Team Kalkine MediaHighlights,Guggenheim has raised its price objective for Vera Therapeutics from $56 to $64, indicating potential upside for the stock.,The company specializes in developing treatments for serious immunological diseases, with its lead product candidat...
BrainStorm Cell Therapeutics successfully restores compliance with Nasdaq requirement
October 30, 2024 03:41 AM PDT| By Team Kalkine MediaHighlights,BrainStorm Cell Therapeutics Inc. has regained compliance with Nasdaq's minimum bid price requirement, ensuring continued listing on The Nasdaq Capital Market.,The company is recognized for its innovative autologous adult stem cell therapi...
Brooklyn ImmunoTherapeutics: Pioneering Innovation in Cancer Treatment
October 29, 2024 10:59 AM PDT| By Team Kalkine MediaHeadlines,Brooklyn ImmunoTherapeutics Gains Momentum,Innovative Treatments for Regenerative Medicine,Exploring New Horizons in Cancer Care,Brooklyn ImmunoTherapeutics (NYSE) has recently seen a positive shift in its stock performance, with an increas...
What Financial Challenges Does Evoke Pharma Face?
October 29, 2024 09:49 AM PDT| By Team Kalkine MediaHighlights,Evoke Pharma Inc. focuses on developing treatments for gastroenterological disorders.,The company is approaching a potential milestone toward profitability.,Concerns about financial stability and capital management remain prevalent.,Evoke...
Analysts Maintain Positive Outlook on AbbVie Inc
October 29, 2024 09:12 AM PDT| By Team Kalkine MediaHeadlines,Analysts have a favorable view of AbbVie Inc.,Recent price targets reflect strong confidence in the company.,Multiple upgrades highlight AbbVie's growth potential.,AbbVie Inc.,(NYSE:ABBV),continues to attract positive attention from analyst...
Global Cord Blood Gains Analyst Attention for Stem Cell Services
October 29, 2024 08:49 AM PDT| By Team Kalkine MediaHeadlines,Global Cord Blood Gains Analyst Attention,Key Services Offered by Global Cord Blood,Future Prospects of Global Cord Blood,Global Cord Blood,(NYSE:CO),has recently attracted interest from analysts who initiated coverage on the company. The b...
What Are the Implications of GlycoMimetics' Latest Move?
October 29, 2024 06:55 AM PDT| By Team Kalkine MediaHighlights,GlycoMimetics enters into an acquisition agreement with Crescent Biopharma.,The combined entity will focus on innovative treatments for solid tumors.,Significant financing secured to support the development of new therapies.,GlycoMimetics...
Novartis's Q3 net profit increase has resulted in a raised annual sales outlook
October 29, 2024 04:46 AM PDT| By Team Kalkine MediaHighlights,Increased Annual Guidance,: Novartis AG revised its annual sales forecast, anticipating growth in low double-digits, reflecting strong performance in the third quarter.,Strong Q3 Financial Results,: The company reported net earnings of $3....
Pfizer's Q3 earnings preview reveals strong growth potential for PFE stock despite market volatility
October 29, 2024 04:26 AM PDT| By Team Kalkine MediaHighlights,Strong Q3 Projections,: Pfizer anticipates an earnings per share (EPS) of $0.61 and revenue of $14.87 billion for Q3, showcasing significant year-over-year growth.,Optimistic Analyst Insights,: J.P. Morgan's projections suggest potential s...
TransMedics (TMDX) Reports Impressive Q3 2024 Financial Results
October 29, 2024 12:54 AM PDT| By Team Kalkine MediaHighlights:,TransMedics achieves 64% revenue growth, reaching $108.8 million in Q3.,The company reports net income of $4.2 million, a significant turnaround from losses.,Maintains full-year revenue guidance, projecting 76-84% growth for 2024.,TransMe...
What Future Challenges Does Beam Therapeutics Face?
October 28, 2024 07:19 AM PDT| By Team Kalkine MediaHighlights,Beam Therapeutics Inc. demonstrates a price-to-sales ratio that stands out within the healthcare sector.,Recent revenue growth has been strong, contrasting with future expectations.,The outlook for revenue raises questions about the sustai...
How Is Eli Lilly Expanding Mounjaro's Market Presence?
October 28, 2024 05:46 AM PDT| By Team Kalkine MediaHighlights,Eli Lilly,(NYSE:LLY),prepares to launch Mounjaro in Hong Kong by the end of the year.,Mounjaro is positioned to be the first drug of its kind available in the broader China region.,The launch is expected to meet rising demand for effective...
